Pemetrexed
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pemetrexed |
| DrugBank ID | DB00642 |
| Brand Names (EU) | Pemetrexed Fresenius Kabi |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Malignant pleural mesothelioma Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Fresenius Kabi is indicated as monothera
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | malignant peritoneal mesothelioma | 99.99% | DL |
| 2 | pleural adenomatoid tumor | 99.99% | DL |
| 3 | pleural mesothelioma | 99.99% | DL |
| 4 | pleural epithelioid mesothelioma | 99.99% | DL |
| 5 | pleural sarcomatoid mesothelioma | 99.99% | DL |
| 6 | pleural biphasic mesothelioma | 99.99% | DL |
| 7 | pericardium cancer | 99.99% | DL |
| 8 | well differentiated papillary mesothelioma | 99.99% | DL |
| 9 | lymphohistiocytoid mesothelioma | 99.99% | DL |
| 10 | malignant mesothelioma (disease) | 99.98% | DL |
| 11 | iminoglycinuria | 99.97% | DL |
| 12 | male infertility with teratozoospermia due to single gene mutation | 99.96% | DL |
| 13 | rhabdomyosarcoma (disease) | 99.93% | DL |
| 14 | botryoid-type embryonal rhabdomyosarcoma of the vagina | 99.93% | DL |
| 15 | extrahepatic bile duct rhabdomyosarcoma | 99.92% | DL |
| 16 | embryonal extrahepatic bile duct rhabdomyosarcoma | 99.92% | DL |
| 17 | parameningeal embryonal rhabdomyosarcoma | 99.92% | DL |
| 18 | prostate embryonal rhabdomyosarcoma | 99.92% | DL |
| 19 | liver sarcoma | 99.91% | DL |
| 20 | liposarcoma | 99.90% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.